Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Brian J. Tunquist"'
Autor:
Darren Pan, Jonathan L. Kaufman, Myo Htut, Manish Agrawal, Amitabha Mazumder, Robert F. Cornell, Jeffrey A. Zonder, Joseph W. Fay, Manuel R. Modiano, Erin L. Moshier, Selena A. Rush, Brian J. Tunquist, Ajai Chari
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 358-370 (2022)
Abstract Filanesib is a first‐in‐class kinesin spindle protein inhibitor which demonstrated safety and encouraging activity in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma in a preliminary analysis of dose
Externí odkaz:
https://doaj.org/article/8ceaef0a12fe48ab866e9efb57eded0b
Supplementary Data from Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1676bc933121c78c7b8503d19a30ad1d
https://doi.org/10.1158/1535-7163.22484846
https://doi.org/10.1158/1535-7163.22484846
Kinesin spindle protein (KSP/Eg5) inhibitors are novel anticancer agents that have thus far shown only modest activity in the clinic. Understanding how to identify patients who may be most sensitive to treatment is clearly needed to improve the devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1231498bf490bc2e6d7326ef6fcb2cbf
https://doi.org/10.1158/1535-7163.c.6531614
https://doi.org/10.1158/1535-7163.c.6531614
Autor:
Darren Pan, Jonathan L. Kaufman, Myo Htut, Manish Agrawal, Amitabha Mazumder, Robert F. Cornell, Jeffrey A. Zonder, Joseph W. Fay, Manuel R. Modiano, Erin L. Moshier, Selena A. Rush, Brian J. Tunquist, Ajai Chari
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 11, Iss 2, Pp 358-370 (2022)
Cancer Medicine, Vol 11, Iss 2, Pp 358-370 (2022)
Filanesib is a first‐in‐class kinesin spindle protein inhibitor which demonstrated safety and encouraging activity in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma in a preliminary analysis of dose‐escala
Autor:
Jonathan L. Kaufman, Robert Z. Orlowski, Selena A Rush, Jeffrey A. Zonder, Walker Duncan H, Adam D. Cohen, Jatin J. Shah, Brandi Hilder, Kevin Litwiler, Mieke Ptaszynski, Brian J. Tunquist, William I. Bensinger, Sagar Lonial
Publikováno v:
Cancer. 123:4617-4630
BACKGROUND Filanesib (ARRY-520) is a highly selective inhibitor of kinesin spindle protein, which has demonstrated preclinical antimyeloma activity. METHODS This open-label Phase 1/2 study determined the maximum tolerated dose of Filanesib administer
Autor:
Steven Michael Burt, Jonathan L. Kaufman, Joseph W. Fay, Kenneth Lau, Jeffrey A. Zonder, Ajai Chari, Brian J. Tunquist, Myo Htut, Selena A Rush, Andrzej Jakubowiak, Joan Levy, Mieke Ptaszynski, Walker Duncan H, Brandi Hilder
Publikováno v:
Cancer. 122:3327-3335
BACKGROUND Filanesib is a kinesin spindle protein inhibitor that has demonstrated encouraging activity in patients with recurrent/refractory multiple myeloma. Preclinical synergy with bortezomib was the rationale for the current phase 1 study. METHOD
Autor:
Ajai, Chari, Myo, Htut, Jeffrey A, Zonder, Joseph W, Fay, Andrzej J, Jakubowiak, Joan B, Levy, Kenneth, Lau, Steven M, Burt, Brian J, Tunquist, Brandi W, Hilder, Selena A, Rush, Duncan H, Walker, Mieke, Ptaszynski, Jonathan L, Kaufman
Publikováno v:
Cancer. 122(21)
BACKGROUND: Filanesib is a kinesin spindle protein inhibitor that has demonstrated encouraging activity in patients with recurrent/refractory multiple myeloma. Preclinical synergy with bortezomib was the rationale for the current phase 1 study. METHO
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.